The T1D Fund, a Breakthrough T1D Venture (formerly the JDRF T1D Fund), is a venture philanthropy fund and wholly owned subsidiary of Breakthrough T1D that catalyzes development of type 1 diabetes treatments, preventions, and cures by co-investing alongside venture capital and biopharma partners in early-stage T1D-focused companies.
78% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $110.1M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$250M
Top Stage
Series B
Last 12 Mo
2
Team
Matt Williams
Director of Operations
Peyman Hosseinchi
Senior Associate
Yash Malliwal
Senior Analyst
Dan McNamara
Head of Strategy and Industry Engagement
Eric Shen
Chief of Staff
Brady Bohrmann
Grant Beard
Joe Lacher, Chair
John Cammett
Karen Jordan
Mike Boyle
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| CCour Pharma | Series B | $50M | Jun 2026 |
 Kriya Therapeutics | Series D | $320M | Sep 2025 |
 Aspect Biosystems | Series B | $115M | Jan 2025 |
 Eledon Pharmaceuticals | Unknown | $85M | Oct 2024 |
 DiogenX | Series A | — | Jan 2023 |
| Kriya Therapeutics | Series B | $100M | Jan 2021 |
| DiogenX | Seed | — | Jan 2020 |
 SQZ Biotech | Series C | $72M | Aug 2018 |
 Provention Bio | Unknown | $28.4M | — |
Top Co-Investors
Last updated: 27 September 2026